teva-english-logo-gray-web-5-1
Photo: Courtesy of Teva
1 March 2017Americas

Actavis and Teva sued over narcotic addiction generic

Speciality pharmaceutical company Orexo has filed a complaint against Actavis and its parent company Teva for infringing patents protecting Orexo’s Suboxone (buprenorphine and naloxone) and Subutex (buprenorphine).

Both of the drugs are used to treat narcotic addiction.

The case, which was filed yesterday, February 28 at the US District Court for the District of Delaware, centres on US patent number 8,454,996.

According to Orexo, Actavis and Teva have infringed the patent by proposing to sell a generic version of Suboxone and Subutex.

Actavis had knowledge of the ‘996 patent as early as May 2014, said the claim, when it sent Orexo an Abbreviated New Drug Application notice letter regarding its proposed generic drug Zubsolv (buprenorphine and naloxone).

In November 2016, Actavis unsuccessfully challenged the validity of the patent involved, as the Delaware court held that the ‘996 patent claims were valid.

Actavis did not appeal against the district court’s decision.

Orexo has now asked the court for a judgment that Actavis and Teva have infringed the ‘996 patent.

The company has also asked for a permanent injunction restraining Actavis from selling the generic products, as well as compensation.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Generics
6 July 2021   Teva Pharmaceuticals has filed lawsuits in New Jersey against two Indian generics manufacturers to stop them from developing a generic version of its Huntington’s disease treatment.
Generics
19 August 2021   The US Court of Appeals for the Federal Circuit has affirmed US Patent Trial and Appeal Board’s decisions upholding three patents related to Teva Pharmaceutical’s migraine drug Ajovy, but has invalidated six others.
Americas
7 September 2021   Teva Pharmaceuticals has abandoned its lawsuit against Amicus Therapeutics, which it had accused of contravening a US federal law designed to help generic makers bring cost-effective biosimilars to market.

More on this story

Generics
6 July 2021   Teva Pharmaceuticals has filed lawsuits in New Jersey against two Indian generics manufacturers to stop them from developing a generic version of its Huntington’s disease treatment.
Generics
19 August 2021   The US Court of Appeals for the Federal Circuit has affirmed US Patent Trial and Appeal Board’s decisions upholding three patents related to Teva Pharmaceutical’s migraine drug Ajovy, but has invalidated six others.
Americas
7 September 2021   Teva Pharmaceuticals has abandoned its lawsuit against Amicus Therapeutics, which it had accused of contravening a US federal law designed to help generic makers bring cost-effective biosimilars to market.

More on this story

Generics
6 July 2021   Teva Pharmaceuticals has filed lawsuits in New Jersey against two Indian generics manufacturers to stop them from developing a generic version of its Huntington’s disease treatment.
Generics
19 August 2021   The US Court of Appeals for the Federal Circuit has affirmed US Patent Trial and Appeal Board’s decisions upholding three patents related to Teva Pharmaceutical’s migraine drug Ajovy, but has invalidated six others.
Americas
7 September 2021   Teva Pharmaceuticals has abandoned its lawsuit against Amicus Therapeutics, which it had accused of contravening a US federal law designed to help generic makers bring cost-effective biosimilars to market.